(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Vote In favor of Your Number one Cell phones - 2Cheetos and Doritos to launch new versions without artificial dyes
- 3The Magnificence of Extraordinariness: Presenting Valuable Adornments and Gemstones
- 41st human missions to Mars should hunt for signs of life, report says
- 5As world leaders enter climate talks, people in poverty have the most at stake
- 10 Demonstrated Systems to Develop Your Internet based Business
- Federal judge upholds Hawaii's new climate change tax on cruise passengers
- Rediscovering Imagination in Adulthood: Individual Creative Excursions
- Exploring the Main Year of Life as a parent: Individual Encounters
- Germany and trade unions kick off tough public-sector wage talks
- The Best Computer games Ever
- Dave Coulier shares new cancer diagnosis 1 year after revealing previous diagnosis
- Geminid meteor shower 2025 peaks next week. Here's what you need to know about this year's best meteor shower
- Feeling wonder every day improves our health. Here’s how to do it.
